Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ADAPT Study: An Open-label, Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

NCT06462547 is registered in ClinicalTrials.gov with Inozyme Pharma as lead sponsor.

NCT NCT06462547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06462547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ADAPT Study: An Open-label, Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
Lead sponsor
Inozyme Pharma
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 19, 2024
Completion date
October 31, 2026
Enrollment
22 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

arterial calcification, autosomal recessive hypophosphatemic rickets type 2, ectonucleotide pyrophosphatase/phosphodiesterase1 deficiency, gene mutations, pseudoxanthoma elasticum